Annotation Detail

Information
Associated Genes
EGFR
Associated Variants
EGFR VIII
EGFR VIII
Associated Disease
head and neck squamous cell carcinoma
Source Database
CIViC Evidence
Description
47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR, and AREG expression by IHC. 17% of cases expressed high levels of EGFRvIII. High vIII expression was associated with reduced disease control rate (DCR) and shortened progression free survival (PFS) (HR: 3.3, P = 0.005) but not with OS.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/848
Gene URL
https://civic.genome.wustl.edu/links/genes/19
Variant URL
https://civic.genome.wustl.edu/links/variants/312
Rating
2
Evidence Type
Predictive
Disease
Head And Neck Squamous Cell Carcinoma
Evidence Direction
Supports
Drug
Docetaxel,Cetuximab
Evidence Level
B
Clinical Significance
Resistance
Pubmed
21653686
Drugs
Drug NameSensitivitySupported
CetuximabResitance or Non-Reponsetrue
DocetaxelResitance or Non-Reponsetrue